{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:11:01Z","timestamp":1783429861319,"version":"3.54.6"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is characterized by a profoundly immunosuppressive microenvironment that fosters active peripheral immune tolerance, thereby severely compromising the efficacy of immune checkpoint inhibitors (ICIs). The recent characterization of cuproptosis\u2014a mitochondrial metabolism-dependent cell death\u2014unveils a novel mechanistic link between metabolic stress and the disruption of this tolerance. This review elucidates the pivotal role of copper death-related long non-coding RNAs (lncRNAs) (CRLs) as epigenetic orchestrators that navigate the delicate balance between immune surveillance and tolerance. We systematically delineate the multifaceted mechanisms through which CRLs drive immune evasion and active immunological tolerance. Rather than a passive failure of the immune system to recognize the tumor, CRLs orchestrate a programmatic remodeling of the microenvironment. This involves (1) actively recruiting immunosuppressive populations, such as regulatory T cells (Tregs) and M2 macrophages, to establish immune exclusion; (2) synergistically upregulating co-inhibitory checkpoints (e.g., PD-L1) to induce effector T cell exhaustion; and (3) functioning as \u201cmolecular brakes\u201d on cuproptosis-induced immunogenicity. Crucially, we highlight the functional heterogeneity of CRLs, identifying a distinct subset of tumor-suppressive lncRNAs (e.g., LINC02362) capable of promoting immunogenic cell death (ICD) to break established peripheral tolerance. Furthermore, we critically evaluate translational strategies, ranging from composite biomarkers to intelligent nanodelivery systems designed to precisely modulate the CRL axis. By shifting the paradigm from \u201cdrug resistance\u201d to \u201ctolerance modulation, \u201c this review provides a strategic roadmap for harnessing CRL-targeted interventions to restore immune homeostasis and sensitize HCC to immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1743964","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:21:00Z","timestamp":1772428860000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting copper death-related long non-coding RNAs: a novel strategy to overcome immunotherapy resistance in liver cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiyang","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengyuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyue","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanteng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12345","article-title":"Tumor-associated macrophages in liver cancer: From mechanisms to therapy","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31706","article-title":"Immune checkpoint inhibitors in combinations for hepatocellular carcinoma","volume":"73","author":"Kalasekar","year":"2021","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115801","article-title":"Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review","volume":"22","author":"Oura","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000237","article-title":"Mechanisms of drug resistance in HCC","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418965","article-title":"The current status and future of targeted-immune combination for hepatocellular carcinoma","volume":"15","author":"Hao","year":"2024","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.01.046","article-title":"Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment","volume":"30","author":"Xu","year":"2022","journal-title":"Mol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-023-01759-1","article-title":"Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma","volume":"22","author":"Hu","year":"2023","journal-title":"Mol Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00876-0","article-title":"Targeting cuproplasia and cuproptosis in cancer","volume":"21","author":"Tang","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-025-02150-9","article-title":"Targeting cuproptosis in liver cancer: Molecular mechanisms and therapeutic implications","volume":"30","author":"Zhou","year":"2025","journal-title":"Apoptosis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118422","article-title":"Cuproptosis: Current insights into its multifaceted role in disease, cancer, and translational\/therapeutic opportunities","volume":"190","author":"Boaru","year":"2025","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s40364-024-00677-8","article-title":"Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy","volume":"12","author":"Zhang","year":"2024","journal-title":"biomark Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12943-024-02130-8","article-title":"Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.06.013","article-title":"Long non-coding RNAs: A new frontier in the study of human diseases","volume":"339","author":"Shi","year":"2013","journal-title":"Cancer Lett"},{"key":"B21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2478\/s11658-014-0212-6","article-title":"Regulation of lncRNA expression","volume":"19","author":"Wu","year":"2014","journal-title":"Cell Mol Biol Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215798","article-title":"LncRNAs in tumor metabolic reprogramming and immune microenvironment remodeling","volume":"543","author":"Yang","year":"2022","journal-title":"Cancer Lett"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954653","article-title":"A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/CBM-220259","article-title":"A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma","volume":"37","author":"Liu","year":"2023","journal-title":"Cancer Bio"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e202400934","DOI":"10.1002\/asia.202400934","article-title":"Cuproptosis: A copper-mediated programmed cell death","volume":"20","author":"Meena","year":"2025","journal-title":"Chem Asian J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13045-022-01392-3","article-title":"Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research","volume":"15","author":"Tong","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","article-title":"Ferroptosis, a new form of cell death: opportunities and challenges in cancer","volume":"12","author":"Mou","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","article-title":"Ferroptosis in cancer therapy: a novel approach to reversing drug resistance","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-051222-115023","article-title":"Apoptosis in cancer biology and therapy","volume":"20","author":"Moyer","year":"2025","journal-title":"Annu Rev Pathol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-024-01545-6","article-title":"Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis","volume":"17","author":"Zhou","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nature14191","article-title":"Necroptosis and its role in inflammation","volume":"517","author":"Pasparakis","year":"2015","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.10.026","article-title":"Autophagy: renovation of cells and tissues","volume":"147","author":"Mizushima","year":"2011","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2020.1797280","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1","volume":"17","author":"Klionsky","year":"2021","journal-title":"Autophagy"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13276","article-title":"Copper homeostasis and cuproptosis in cancer immunity and therapy","volume":"321","author":"Liu","year":"2024","journal-title":"Immunol Rev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41392-022-01229-y","article-title":"Copper homeostasis and cuproptosis in health and disease","volume":"7","author":"Chen","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109518","article-title":"Copper transporter gene ATP7A: A predictive biomarker for immunotherapy and targeted therapy in hepatocellular carcinoma","volume":"114","author":"Shao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189180","article-title":"Unveiling Cuproptosis: Mechanistic insights, roles, and leading advances in oncology","volume":"1879","author":"Zhang","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-024-01589-8","article-title":"Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103302","article-title":"FDX1 downregulation activates mitophagy and the PI3K\/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production","volume":"75","author":"Sun","year":"2024","journal-title":"Redox Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated TCA cycle proteins","volume":"375","author":"Tsvetkov","year":"2022","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122223","article-title":"Copper homeostasis and cuproptosis in mitochondria","volume":"334","author":"Tian","year":"2023","journal-title":"Life Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41419-023-06264-3","article-title":"MELK promotes HCC carcinogenesis through modulating cuproptosis-related gene DLAT-mediated mitochondrial function","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12935-025-03683-4","article-title":"Cuproplasia and cuproptosis in hepatocellular carcinoma: mechanisms, relationship and potential role in tumor microenvironment and treatment","volume":"25","author":"Zhang","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1290592","article-title":"Research progress on cuproptosis in cancer","volume":"15","author":"Feng","year":"2024","journal-title":"Front Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202400652","article-title":"Cuproptosis: advances in stimulus-responsive nanomaterials for cancer therapy","volume":"13","author":"Lu","year":"2024","journal-title":"Adv Healthc Mater"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1097075","article-title":"Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma","volume":"14","author":"Lu","year":"2023","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991604","article-title":"Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma","volume":"13","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13062-023-00358-w","article-title":"Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma","volume":"18","author":"Chen","year":"2023","journal-title":"Biol Direct"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-022-10381-0","article-title":"Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC","volume":"16","author":"Wang","year":"2022","journal-title":"Hepatol Int"},{"key":"B51","article-title":"LINC02362\/hsa-miR-18a-5p\/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma","volume":"13","author":"Quan","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1153353","article-title":"Identification of a cuproptosis and copper metabolism gene\u2013related lncRNAs prognostic signature associated with clinical and immunological characteristics of hepatocellular carcinoma","volume":"13","author":"Yuan","year":"2023","journal-title":"Front Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12859-022-05091-1","article-title":"Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma","volume":"24","author":"Liu","year":"2023","journal-title":"BMC Bioinf"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3892\/ijmm.2020.4722","article-title":"Long non\u2212coding RNA MKLN1\u2212AS aggravates hepatocellular carcinoma progression by functioning as a molecular sponge for miR\u2212654\u22123p, thereby promoting hepatoma\u2212derived growth factor expression","volume":"46","author":"Gao","year":"2020","journal-title":"Int J Mol Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061800","article-title":"Integrated analysis of N1-methyladenosine methylation regulators-related lncRNAs in hepatocellular carcinoma","volume":"15","author":"Song","year":"2023","journal-title":"Cancers"},{"key":"B56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12935-023-03208-x","article-title":"Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma","volume":"24","author":"Xu","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1056000","article-title":"An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma","volume":"14","author":"Chen","year":"2023","journal-title":"Front Genet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2021.104638","article-title":"Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma","volume":"120","author":"Guo","year":"2021","journal-title":"Exp Mol Pathol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.08.024","article-title":"Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells","volume":"79","author":"Meng","year":"2023","journal-title":"J Hepatol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1038\/s41467-021-24010-1","article-title":"Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma","volume":"12","author":"Ho","year":"2021","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mco.2025.2912","article-title":"A 4\u2212cuproptosis\u2212related lncRNA theragnostic signature predicts survival and immunotherapy response in patients with lung adenocarcinoma","volume":"24","author":"Lu","year":"2025","journal-title":"Mol Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1115608","article-title":"A novel cuproptosis-related prognostic 2-lncRNAs signature in breast cancer","volume":"13","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.957966","article-title":"A novel cuproptosis-related lncRNA nomogram to improve the prognosis prediction of gastric cancer","volume":"12","author":"Feng","year":"2022","journal-title":"Front Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12943-022-01684-9","article-title":"A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer","volume":"21","author":"Guo","year":"2022","journal-title":"Mol Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0541","article-title":"Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications","volume":"31","author":"Park","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with galNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00521-4","article-title":"Targeting RNA structures with small molecules","volume":"21","author":"Childs-Disney","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR\u2013cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-21-517","article-title":"Two is better than one: combinatorial receptor targeting enhances hepatocellular carcinoma (HCC) therapeutic response","volume":"11","author":"Sequera","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B70","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s11658-024-00608-3","article-title":"Cuproptosis in cancer: biological implications and therapeutic opportunities","volume":"29","author":"Li","year":"2024","journal-title":"Cell Mol Biol Lett"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-0471","article-title":"Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion","volume":"80","author":"Voli","year":"2020","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116874","article-title":"Cuproptosis in cancers: Function and implications from bench to bedside","volume":"176","author":"Huang","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e202100045","DOI":"10.1002\/anse.202100045","article-title":"Copper-catalyzed covalent dimerization of near-infrared fluorescent cyanine dyes: synergistic enhancement of photoacoustic signals for molecular imaging of tumors","volume":"2","author":"Maji","year":"2022","journal-title":"Anal Sens"},{"key":"B74","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/j.semnuclmed.2024.10.002","article-title":"Copper-64 based PET-radiopharmaceuticals: ways to clinical translational","volume":"54","author":"Yang","year":"2024","journal-title":"Semin Nucl Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01158","article-title":"Effect of structural modifications to glyoxal-bis(thiosemicarbazonato)copper(II) complexes on cellular copper uptake, copper-mediated ATP7A trafficking, and P-glycoprotein mediated efflux","volume":"61","author":"Acevedo","year":"2018","journal-title":"J Med Chem"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2902052","article-title":"Drug resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"29","author":"Lei","year":"2024","journal-title":"Front Biosci (Landmark Ed)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1743964\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:21:02Z","timestamp":1772428862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1743964\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":76,"alternative-id":["10.3389\/fimmu.2026.1743964"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1743964","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"article-number":"1743964"}}